Current as of 2026-11-06. Coverage rules and FDA labeling change. Verify with your own clinician, and with TRICARE or your regional contractor, before acting on any of it.
Short answer: Perimenopause and menopause are normal changes, and many military spouses go through them while moving with the service. TRICARE says hormone therapy is covered through the pharmacy benefit, with limits: the drug must be FDA approved and prescribed for its labeled uses. Hormone therapy is not the only option, and it is not right for everyone. A good plan starts with a clinician who knows your history and who stays reachable when your orders change.
This article is general information, not medical advice. It cannot tell you what is right for your body.
What perimenopause and menopause are
The FDA describes menopause as a normal, natural change in a woman's life when her period stops. You have reached it when you have gone 12 months in a row without a period. The FDA says this often happens between ages 45 and 55.
Perimenopause is the stretch before that, when your cycle starts to change. The NIH's NICHD says it begins with a change in the menstrual cycle. Periods may be irregular, longer or shorter, lighter or heavier.
Symptoms worth knowing about
NICHD lists these as common:
- Hot flashes, which can last from about 30 seconds to 10 minutes
- Night sweats and sleep problems
- Vaginal dryness, which can make sex uncomfortable and raise the risk of vaginal or urinary tract infections
- Urine leakage when you sneeze, cough, laugh, or run
- Changes in sex drive, in either direction
- Mood changes such as irritability or anxiety
The FDA also notes that some women have no symptoms beyond the end of their periods. So your experience may look different from a friend's, and both can be normal.
NICHD adds that pregnancy is still possible during perimenopause, so contraception still matters if pregnancy would be a concern.
What the evidence says about treatment options
The FDA says treatments for menopausal symptoms include hormone therapy and non-hormonal therapy, and that menopause hormone therapy is not for everyone.
Hormone therapy. The Menopause Society (formerly NAMS) 2022 position statement says hormone therapy remains the most effective treatment for hot flashes and night sweats (vasomotor symptoms) and for the genitourinary syndrome of menopause, and that it has been shown to prevent bone loss and fracture. The same statement says risks differ by type, dose, duration, route, timing of starting, and whether a progestogen is used. It calls for individualized treatment with periodic reevaluation.
On timing, the statement says that for women younger than 60 or within 10 years of menopause onset with no contraindications, the benefit-risk balance is favorable for bothersome hot flashes. For women who start more than 10 years after menopause onset or after age 60, it says the balance appears less favorable.
Vaginal estrogen. For bothersome genital and urinary symptoms that over-the-counter products do not relieve, in women with no reason to use systemic hormone therapy, the statement recommends low-dose vaginal estrogen or other therapies such as vaginal DHEA or oral ospemifene.
Non-hormonal prescriptions. The Menopause Society's patient handout lists fezolinetant as a government-approved non-hormone option for bothersome hot flashes, along with paroxetine. The FDA approved elinzanetant (Lynkuet) on October 24, 2025 to reduce moderate to severe hot flashes caused by menopause.
The boxed warning, and what changed
For years, menopausal hormone therapy labels carried a boxed warning. On November 10, 2025, the FDA announced it was starting to remove the broad warnings about cardiovascular disease, breast cancer, and probable dementia. On February 12, 2026, it announced approved label changes that removed those risk statements from the boxed warning for the first products. The boxed warning for endometrial cancer stays for systemic estrogen-alone products.
The FDA says the updated labeling recommends starting systemic therapy within 10 years of menopause onset or before age 60, and leaves decisions about when to start and how long to continue to the prescriber and patient.
A label change does not make hormone therapy risk-free. It means the warning language moved. The Menopause Society handout still describes possible risks, including a slight increase in stroke or blood clots, and says combined estrogen and progestogen might slightly increase breast cancer risk if used for more than 4 to 5 years. Those details depend on you, which is why this is a conversation with your own clinician.
What TRICARE says about coverage
TRICARE's page on hormone replacement therapy says it is covered through the TRICARE pharmacy benefit. Prescribed drugs must be FDA approved and prescribed in accordance with labeled indications. The page points to the TRICARE Formulary Search Tool for specific drugs. TRICARE's FAQ answers the question "Does TRICARE cover hormone replacement therapy?" with "Yes, but there are some limitations."
The page also says TRICARE covers services that are medically necessary and considered proven, and that some services have special rules or limits. It does not discuss compounded drugs or list specific menopause visits, so we cannot tell you from it whether a given compounded product or a given office visit is covered. Call TRICARE or check the formulary tool for the exact drug and dose you have in mind.
Moving with TRICARE, and keeping your care continuous
Menopause care often needs adjusting over months. A PCS can interrupt that.
TRICARE's moving page says your eligibility does not change when you move, but your health plan options may. It says not to disenroll from any plan before you move, to update your address in DEERS afterward, and that you have 90 days from the date of your address change to change your TRICARE plan. For Prime, the Moving with Prime page says to transfer your coverage within 90 days of arriving.
One practical habit: before you pack, ask your current prescriber for your records, a list of your medications with doses and the form you use (patch, gel, pill, vaginal), and a summary of why you started. Those few pages let a new clinician pick up where the last one stopped.
Wait times
TRICARE's access-to-care standards for appointments with TRICARE network providers are up to 1 week for routine care and up to 4 weeks for specialty care. The page does not say whether those standards apply to military hospitals and clinics. We found no official source we could verify on how long women actually wait for menopause care at military treatment facilities, so we are not going to guess at one.
When to see a clinician
NICHD says women should consult a healthcare provider for heavy bleeding, periods very close together, spotting, or periods lasting longer than a week. Beyond that, a visit makes sense when symptoms disrupt your sleep, your work, your relationships, or your day. You do not need to wait for symptoms to be severe.
A note on compounded and bioidentical products
The word "bioidentical" gets used for two different things. The Menopause Society says the term can be misleading because there are both FDA-approved bioidentical hormones, which include estradiol and are regulated and monitored for purity and efficacy, and compounded versions made by a pharmacist from a prescription.
The FDA says it does not have evidence that compounded "bioidentical hormones" are safe and effective, and that compounded drugs are not FDA approved, so the agency does not review their safety, effectiveness, or quality before they are marketed. The Menopause Society statement says there is insufficient evidence to support overall clinical use of compounded bioidentical hormone therapy for menopause symptoms, and that it could be considered in situations such as an allergy to an ingredient in an approved product or a dose that approved products do not offer. Ask any prescriber which kind you are being offered. This also bears on TRICARE, because its page ties coverage to FDA-approved drugs used as labeled.
Questions people actually ask
Does TRICARE cover hormone therapy for menopause? TRICARE says hormone replacement therapy is covered through the pharmacy benefit, for FDA-approved drugs prescribed for labeled uses, with some limitations. Check the formulary tool for your specific drug.
Is hormone therapy the only treatment? No. The FDA says non-hormonal therapies exist, and the Menopause Society handout names fezolinetant and paroxetine for hot flashes. Your clinician can talk through which fits your history.
Did the FDA remove the warning on hormone therapy? It removed the cardiovascular disease, breast cancer, and probable dementia statements from the boxed warning on approved products. The endometrial cancer boxed warning remains for systemic estrogen-alone products.
Is there an age cutoff? The FDA's updated labeling recommends starting systemic therapy within 10 years of menopause onset or before 60. The Menopause Society says the balance looks less favorable after that. Individual circumstances vary.
What do I do about my records when we PCS? Get copies and a medication list before you leave, and plan the plan-change step within 90 days of your address change.
Where we fit
Hew Health is a private, cash-pay practice. We do not bill TRICARE, and for many spouses the TRICARE pharmacy and network route is a perfectly good place to start. If it is working for you, you may not need us.
Some women look for a private option because they want longer visits, because they are between duty stations, or because they want one clinician they can reach by telemedicine from any address. We see patients in Destin and Orlando, Florida, and by telemedicine in 47 states. If you come to us, we will ask about your history, explain what is and is not FDA approved, and tell you plainly when something is outside what we should treat. We make no promises about results, and the right plan depends on you.
If you would like to talk, you can request a consultation at hewhealth.com or call (850) 820-8850.
Related dispatches
- Does TRICARE Cover Testosterone Replacement Therapy?
- Getting Out on TRT: The Gap Between TRICARE and the VA
- Deploying on Testosterone: Waivers, Supply, and What You Cannot Mail
Hew Health is a private medical practice. We are not affiliated with, endorsed by, or connected to the Department of Defense, TRICARE, or any branch of the U.S. Armed Forces. This article is general information, not medical advice, and is current as of 2026-11-06. Coverage rules and FDA labeling change.
Sources: FDA, "Menopause" (consumer page). FDA press announcements of November 10, 2025 and February 12, 2026 on menopausal hormone therapy labeling. FDA, "Understanding the Risks of Compounded Drugs." FDA Drug Trials Snapshots: LYNKUET. NICHD, "What are the symptoms of menopause?" The 2022 hormone therapy position statement of The North American Menopause Society (Menopause Society). Menopause Society MenoNote, "Deciding About Hormone Therapy Use." TRICARE: Hormone Replacement Therapy, FAQ on hormone therapy, Access to Care Standards, Moving, Moving with Prime.